EGEN-5784
Acute-on-chronic liver failure (ACLF) with extracorporeal support
IND ClearedActive
Key Facts
Indication
Acute-on-chronic liver failure (ACLF) with extracorporeal support
Phase
IND Cleared
Status
Active
Company
About eGenesis
eGenesis is a clinical-stage biotech developing human-compatible organs from genetically engineered pigs to solve the critical shortage of donor organs. The company's platform utilizes multiplex CRISPR-based gene editing to inactivate endogenous retroviruses, knock out immunogenic antigens, and insert human protective genes. With an FDA-cleared IND for its lead kidney program (EGEN-2784) now in a Phase 1/2/3 trial and a second IND for a liver program (EGEN-5784), eGenesis is a leader in advancing xenotransplantation from concept to clinical reality. The company is privately held and backed by prominent life science investors.
View full company profile